Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial-Reference-Cited by-同舟云学术

Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial

Published:2008 Issue:3 Volume:23 Page:211-216
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol. Clin. Exp.

Author:

Chawla Bharat,Luxton-Andrew Heather

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology,Neurology

Reference26 articles.

1. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients

2. Metformin for Prevention of Weight Gain and Insulin Resistance with Olanzapine: A Double-Blind Placebo-Controlled Trial

3. , , et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. Poster presented at the 157th Annual Meeting of the American Psychiatric Association, 1–6 May 2004. New York, USA.

4. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia

5. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olanzapine;Meyler's Side Effects of Drugs;2016

2. Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis;PLoS ONE;2014-04-24

3. Management of Antipsychotic-Induced Weight Gain;Psychopharm Review;2013-07

4. Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study;Human Psychopharmacology: Clinical and Experimental;2012-03-31

5. Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2012-03